After reading this article, the practitioner should be able to:
- Summarize key questions about the use of antipsychotic agents in the treatment of schizophrenia and describe the context in which the National Institute of Mental Health-sponsored Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) in schizophrenia was conducted.
- Describe CATIE's major findings about comparative effectiveness of four second-generation antipsychotics (risperidone, olanzapine, quetiapine, and ziprasidone) and one first-generation antipsychotic (perphenazine) in the treatment of schizophrenia.
- Discuss the clinical implications of CATIE in the context of its methodologic constraints, and summarize what can and cannot be learned from this study.
Dr. Tandon is Chief of Psychiatry, Florida Program of Mental Health, and Adjunct Professor of Psychiatry, University of Florida, Room 235, Building 6, 1317 Winewood Boulevard, Tallahassee, FL 32399-0700; E-mail: firstname.lastname@example.org.
The author has disclosed that he has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity.
Lippincott CME Institute, Inc., has identified and resolved all faculty conflicts of interest regarding this educational activity.